ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39358463

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Tan Y and 14 others. Cancer Immunol Immunother, 2024. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. Papers, record 39358463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39358463

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.53, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tan YYang
2Liu KKai
3Zhu CChengpei
4Wang SShanshan
5Wang YYunchao
6Xue JJingnan
7Ning CCong
8Zhang NNan
9Chao JJiashuo
10Zhang LLonghao

1 to 10 of 15Source PubMed

See all 15 authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gallbladder NeoplasmsMajor topic
QuinolinesMajor topic
Phenylurea CompoundsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
DeoxycytidineMajor topic
Humans
Female
Male
Middle Aged
Aged
Retrospective Studies
Adult
Immune Checkpoint Inhibitors
Gemcitabine
Aged, 80 and over
Organoplatinum Compounds

Source PubMed

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
[Y-HR2019-0239] [Y-HR2020QN-0414]CSCO-hengrui Cancer Research FundPubMed
[Y-HR2019-0239] [Y-HR2020QN-0414]CSCO-hengrui Cancer Research FundPubMed
(No. Qiankehe Foundation [2020] 1Y302)the Department of Science and Technology of Guizhou ProvincePubMed
(No. 81960125)the National Natural Science Foundation of China (NSFC)PubMed
[2022-PUMCH-B-128]National High Level Hospital Clinical Research FundingPubMed
[2022-I2M-C&T-A-003] [2021-I2M-1-061] [2021-I2M-1-003]CAMS Innovation Fund for Medical Sciences（CIFMS）PubMed
[Y-MSDZD2021-0213]CSCO-MSD Cancer Research FundPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in40,257,503Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.https://conductscience.org/library/papers/40257503

Source PubMed

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,516,341Biliary tract cancer.Lancet2021https://conductscience.org/library/papers/33516341PubMed
233,538,338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
320,375,404Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010https://conductscience.org/library/papers/20375404PubMed
433,798,493Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Lancet Oncol2021https://conductscience.org/library/papers/33798493PubMed
534,656,226
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Lancet Oncol2021https://conductscience.org/library/papers/34656226PubMed
633,592,561First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!"Cancer Treat Res Commun2021https://conductscience.org/library/papers/33592561PubMed
733,172,881Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.J Immunother Cancer2020https://conductscience.org/library/papers/33172881PubMed
832,487,569Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.J Immunother Cancer2020https://conductscience.org/library/papers/32487569PubMed
938,319,896Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.NEJM Evid2022https://conductscience.org/library/papers/38319896PubMed
1036,928,584Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36928584PubMed

1 to 10 of 37

See all 37 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42,626,346New progress and clinical research translation of immune checkpoint inhibitors in systemic therapy of gallbladder cancer.Front Immunol2026https://conductscience.org/library/papers/42626346PubMed
41,080,570Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review.Front Immunol2025https://conductscience.org/library/papers/41080570PubMed
40,341,972Predicting treatment response to systemic therapy in advanced gallbladder cancer using multiphase enhanced CT images.Eur Radiol2025https://conductscience.org/library/papers/40341972PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39358463

GET https://conductscience.org/api/papers/v1/39358463/references?page=2

API referenceFor AI assistants